Status:
COMPLETED
Human Epididymis Protein 4 in Endometrial Carcinoma
Lead Sponsor:
Ain Shams University
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
45-70 years
Brief Summary
Endometrial cancer represents the most common gynecologic cancer, and it is expected to become an even greater public health concern as the prevalence of obesity, one of the most common risk factors f...
Detailed Description
Human epididymis protein 4, a putative protease inhibition containing two Whey Acid Protein domains, is significantly increased in the endometrioid subtype of endometrial carcinoma. Tissue microarray...
Eligibility Criteria
Inclusion
- Age (45 - 70 yr old).
Exclusion
- Age more than 70 yr and less than 40 yr.
- Abnormal cardiac hematological renal hepatic functions.
- Breast cancer or other malignancies.
- Concomitant benign and for malignant adnexal pathologies.
- Hormonal medication.
- Patient taking or having chemo-radiotherapy.
- Patients unfit for surgical intervention.
- Smoker.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2018
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03456791
Start Date
December 1 2017
End Date
July 30 2018
Last Update
August 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Egypt